JonesResearch downgraded Decibel Therapeutics (DBTX) to Hold from Buy after Decibel agreed to be acquired by Regeneron (REGN) for $4.00 per share along with a non-tradeable contingent value right, or CVR, to receive up to $3.50 per share in cash subsequent achievement of certain milestones related to DB-OTO.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on DBTX: